# Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

> **NCT01900782** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Intervention A
- **BIOLOGICAL:** Intervention B
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01900782
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900782, "Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01900782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*